Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 144

Similar articles for PubMed (Select 23525731)

1.

Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.

Kerr EH, Frederick PJ, Egger ME, Stockard CR, Sellers J, DellaManna D, Oelschlager DK, Amm HM, Eltoum IE, Straughn JM, Buchsbaum DJ, Grizzle WE, McNally LR.

Ann Surg Oncol. 2013 Sep;20(9):3059-65. doi: 10.1245/s10434-013-2878-9. Epub 2013 Mar 24.

PMID:
23525731
2.

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.

Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, Piché A.

BMC Cancer. 2015 Jul 1;15:492. doi: 10.1186/s12885-015-1511-7.

3.

Survivin siRNA increases sensitivity of primary cultures of ovarian cancer cells to paclitaxel.

Kar R, Palanichamy JK, Banerjee A, Chattopadhyay P, Jain SK, Singh N.

Clin Transl Oncol. 2015 Jun 2. [Epub ahead of print]

PMID:
26033427
4.

Renal cell carcinoma presenting with malignant ascites.

Jennison E, Wathuge GW, Gorard DA.

JRSM Open. 2015 May 11;6(4):2054270415585087. doi: 10.1177/2054270415585087. eCollection 2015 Apr.

5.
6.

CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.

Nymoen DA, Holth A, Hetland Falkenthal TE, Tropé CG, Davidson B.

Mol Cancer. 2015 Feb 18;14:44. doi: 10.1186/s12943-015-0317-1.

7.

Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer.

Gao Y, Foster R, Yang X, Feng Y, Shen JK, Mankin HJ, Hornicek FJ, Amiji MM, Duan Z.

Oncotarget. 2015 Apr 20;6(11):9313-26.

8.

Presence of both Mesenchymal and Carcinomatous Features in an In-vitro Model of Ovarian Carcinosarcoma Derived from Patients' Ascitic Fluid.

Shariftabrizi A, Pellicciotta I, Abdullah A, Venditti CA, Samuelson R, Shahabi S.

Int J Hematol Oncol Stem Cell Res. 2015 Jan 1;9(1):1-4.

9.

Prolonged response to aflibercept in ovarian cancer relapse: a case report.

Redondo A, Castelo B, Pinto A, Zamora P, Espinosa E.

Tumori. 2015 Mar 20;101(1):e29-31. doi: 10.5301/tj.5000202.

PMID:
25702661
10.

Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.

Stefanou DT, Bamias A, Episkopou H, Kyrtopoulos SA, Likka M, Kalampokas T, Photiou S, Gavalas N, Sfikakis PP, Dimopoulos MA, Souliotis VL.

PLoS One. 2015 Feb 6;10(2):e0117654. doi: 10.1371/journal.pone.0117654. eCollection 2015.

11.
12.

High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers.

Miyamoto M, Takano M, Iwaya K, Shinomiya N, Goto T, Kato M, Suzuki A, Aoyama T, Hirata J, Nagaoka I, Tsuda H, Furuya K.

Br J Cancer. 2015 Feb 17;112(4):739-44. doi: 10.1038/bjc.2015.1. Epub 2015 Jan 27.

PMID:
25628093
13.

Identification of microRNAs and target genes involved in serous ovarian carcinoma and their influence on survival.

Wang L, Wang B, Fang M, Guo F, Cui M.

Eur J Gynaecol Oncol. 2014;35(6):655-61.

PMID:
25556270
14.

Very late recurrence (after more than 20 years) of epithelial ovarian carcinoma: case report and literature review.

Menczer J, Schreiber L, Peled O, Levy T.

Arch Gynecol Obstet. 2015 Jun;291(6):1199-203. doi: 10.1007/s00404-014-3597-6. Epub 2014 Dec 19.

PMID:
25524538
15.

Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.

Bonneau C, Rouzier R, Geyl C, Cortez A, Castela M, Lis R, Daraï E, Touboul C.

Gynecol Oncol. 2015 Jan;136(1):112-20. doi: 10.1016/j.ygyno.2014.10.024. Epub 2014 Nov 1.

PMID:
25449309
16.

Clinical applicability of multi-tumor marker protein chips for diagnosing ovarian cancer.

Bian J, Li B, Kou XJ, Wang XN, Sun XX, Ming L.

Asian Pac J Cancer Prev. 2014;15(19):8409-11.

17.

Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication.

Shender VO, Pavlyukov MS, Ziganshin RH, Arapidi GP, Kovalchuk SI, Anikanov NA, Altukhov IA, Alexeev DG, Butenko IO, Shavarda AL, Khomyakova EB, Evtushenko E, Ashrafyan LA, Antonova IB, Kuznetcov IN, Gorbachev AY, Shakhparonov MI, Govorun VM.

Mol Cell Proteomics. 2014 Dec;13(12):3558-71. doi: 10.1074/mcp.M114.041194. Epub 2014 Sep 30.

PMID:
25271300
18.

Molecular subtypes of high-grade serous ovarian cancer: the holy grail?

Waldron L, Riester M, Birrer M.

J Natl Cancer Inst. 2014 Sep 30;106(10). pii: dju297. doi: 10.1093/jnci/dju297. Print 2014 Oct. No abstract available.

PMID:
25269490
19.

Metabolic markers and HSP60 in chemonaive serous solid ovarian cancer versus ascites.

Hjerpe E, Brage SE, Frostvik Stolt M, Johansson H, Shoshan M, Avall-Lundqvist E.

Int J Gynecol Cancer. 2014 Oct;24(8):1389-94. doi: 10.1097/IGC.0000000000000246.

PMID:
25188891
20.

Control values of ovarian cancer tumor markers and standardisation of a protocol for sampling peritoneal fluid and performing washing during laparoscopy.

Galic Jerman K, Kobal B, Jakimovska M, Verdenik I, Cerne K.

World J Surg Oncol. 2014 Sep 4;12:278. doi: 10.1186/1477-7819-12-278.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk